Denosumab does not decrease the risk of lung metastases from bone giant cell tumour

Tsukamoto, Shinji; Mavrogenis, Andreas F.; Leone, Giulio; Righi, Alberto; Akahane, Manabu; Tanzi, Piergiuseppe; Kido, Akira; Honoki, Kanya; Tanaka, Yasuhito; Donati, Davide María; Errani, Costantino

doi:10.1007/s00264-018-4085-6

Cited by 23 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is not clear whether denosumab treatment can also suppress lung metastasis in patients with GCTB. Recent studies describe that denosumab did not show any effect on reducing tumor recurrence and that denosumab did not decrease the risk of lung metastases in patients with GCTB . CO3 is a protein of the immune system that plays a central role in the complement system and contributes to innate immunity .…”

Section: Discussionmentioning

confidence: 99%

Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treatment in Giant Cell Tumors of Bone

Suehara

Okubo

Kurihara

et al. 2019

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose Giant cell tumors of bone (GCTBs) are locally aggressive osteolytic bone tumors. Denosumab is a novel and effective therapeutic option for aggressive and recurrent GCTBs. Histologically, the post‐denosumab‐treated samples are characterized by two lesions: a residual stromal cell lesion with a few multinucleated giant cells (SL‐lesion), and a fibro‐osseous lesion (FO‐lesion). Experimental design To clarify the differences in the protein expression between the SL‐lesion and FO‐lesion in GCTB treated with denosumab, comparative proteomic studies are conducted using both lesions (12 pairs of pre‐ and post‐denosumab treatment samples) by isobaric tags for relative and absolute quantification (i‐TRAQ). Results Thirty‐two consistently regulated proteins in the SL‐lesions and 59 consistently regulated proteins in the FO‐lesions are found. Twenty‐one proteins in the SL‐lesion and 48 proteins in the FO‐lesion are independently expressed. These proteins may be involved in the process of the fibro‐osseous reactions by denosumab treatment. In the software program used to establish these profiles, several canonical pathways are identified, including the unfolded protein response as an FO‐lesion specific pathway. Conclusions and clinical relevance It is believed that the identified proteins and the results of the network analysis will provide a better understanding of the effects of denosumab in GCTB.

show abstract

Section: Discussionmentioning

confidence: 99%

Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treatment in Giant Cell Tumors of Bone

Suehara

Okubo

Kurihara

et al. 2019

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…Complications and others 6 studies [9,13,15,19,21,22] reported denosumab-related complications, in the 388 cases treated with denosumab, no osteo-necrosis of jaw or hypocalcemia was observed. 1 study [13] reported a periapical abscess and a periodontal disease during the course of denosumab administration. No other denosumab-related complications were reported in all included studies.…”

Section: Recurrence Free Survivalmentioning

confidence: 93%

“…The total dosage given prior to surgery was inconsistent among included studies. 4 studies [13,[15][16][17] administered denosumab pre-operatively and post-operatively. Overall, 61 cases in the denosumab group and 175 cases in the control group had local recurrence.…”

Section: Recurrencementioning

confidence: 99%

“…In 4 studies [13,[15][16][17] denosumab was administered both preoperatively and postoperatively, no statistically significant difference was found when comparing pre and post denosumab administration group and control group in terms of local recurrence(OR: 1.96, 95% CI: 0.63 to 6.07, p=0.24, I 2 =79%) ( Figure 5).…”

Section: Recurrencementioning

confidence: 99%

“…Scoccianti et al [9] conducted dental check before denosumab administration. Oral supplementary of Vitamin D and calcium is administered in 4 studies [3,9,13,19].Generally, Vitamin D was given more than 400IU/day and calcium more than 500mg/day. Administration of denosumab were similar, most studies administered denosumab once a month with 1-3 additional doses during the first month, the duration of administration prior to surgery differs for various reasons.…”

Section: Recurrence Free Survivalmentioning

confidence: 99%

See 2 more Smart Citations

Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

Chen

Zhu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity. It is suggested that denosumab relives pain, facilitate curettage in lesions requiring resection initially. However, controversy remains whether denosumab increases the risk of local recurrence after surgery.Methods: Medline, Embase and the Cochrane Library were comprehensively searched in June 2019 to identify studies investigating the clinical outcome of GCT of bone with and without peri-operative denosumab after surgery. Data were gathered and a meta-analysis was conducted.Result: Ten studies with 1082 cases (169 in denosumab group, 913 in control group) were included.Overall, denosumab was associated with significantly higher risk of recurrence(P<0.02) and inferior 5year recurrence free survival(P=0.000). Denosumab and curettage has a relatively higher risk of recurrence comparing to curettage alone(P=0.07). The risk of recurrence is not significantly increased if denosumab was administered both preoperatively and postoperatively(P=0.24).Conclusion: Administration of denosumab is associated with increased risk of recurrence due to a variety of reasons, though it is proven effective in relieving pain, enabling curettage and improved functional outcome. Post-operative denosumab is recommended as it continuously suppress/eliminate residue tumor cells.

show abstract

Pulmonary metastasis of giant cell tumour: a retrospective study of three hundred and ten cases

Wang

Liu

Yang

et al. 2021

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

Denosumab does not decrease the risk of lung metastases from bone giant cell tumour

Cited by 23 publications

References 26 publications

Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treatment in Giant Cell Tumors of Bone

Protein Expression Profiles Corresponding to Histological Changes with Denosumab Treatment in Giant Cell Tumors of Bone

Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

Pulmonary metastasis of giant cell tumour: a retrospective study of three hundred and ten cases

Contact Info

Product

Resources

About